Review



old boyj cd45 1 recipient mice  (Jackson Laboratory)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Jackson Laboratory old boyj cd45 1 recipient mice
    TLK2 ASO in combination with gilteritinib decreases leukemic burden in a murine model of AML. (A) A schematic representation of a murine AML bone marrow transplantation model. 1e6 lineage (Lin - )-depleted <t>CD45.2</t> + LysM-Cre + Flt3 ITD Tet2 +/- bone marrow cells were injected into lethally <t>irradiated</t> <t>CD45.1</t> + recipients. Mice were treated with NT ASO, TLK2 ASO, NT ASO + gilteritinib, or TLK2 ASO + gilteritinib. (B) TLK2 expression in peripheral blood at week 17. (C) Spleen size measured by ultrasound at 14 weeks post-transplantation. (D) Endpoint spleen weights at 19 weeks post-transplantation. (E) Spleen images from each treatment group. (F) Leukemic burden in the bone marrow at 19 weeks post-transplantation was measured by flow cytometry using CD45.2 + and myeloid marker Ly6GLy6C. (G) Number of Lin - c-Kit + population and Lin - c - Kit + Sca - 1 + population in the bone marrow at week 19. (H) 2, 500 lineage-negative bone marrow cells from LysM-Cre + Flt3 ITD Tet2 +/- mouse were plated in methylcellulose-based media and treated with 10 µM NT ASO or TLK2 ASO, either alone or in combination with 200 nM gilteritinib. Colonies were counted on day 6. Data was presented in duplicates. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001) as determined by one-way ANOVA.
    Old Boyj Cd45 1 Recipient Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/old+boyj+cd45+1+recipient+mice/pmc13006219-73-12-17?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    old boyj cd45 1 recipient mice - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia"

    Article Title: Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2026.1659341

    TLK2 ASO in combination with gilteritinib decreases leukemic burden in a murine model of AML. (A) A schematic representation of a murine AML bone marrow transplantation model. 1e6 lineage (Lin - )-depleted CD45.2 + LysM-Cre + Flt3 ITD Tet2 +/- bone marrow cells were injected into lethally irradiated CD45.1 + recipients. Mice were treated with NT ASO, TLK2 ASO, NT ASO + gilteritinib, or TLK2 ASO + gilteritinib. (B) TLK2 expression in peripheral blood at week 17. (C) Spleen size measured by ultrasound at 14 weeks post-transplantation. (D) Endpoint spleen weights at 19 weeks post-transplantation. (E) Spleen images from each treatment group. (F) Leukemic burden in the bone marrow at 19 weeks post-transplantation was measured by flow cytometry using CD45.2 + and myeloid marker Ly6GLy6C. (G) Number of Lin - c-Kit + population and Lin - c - Kit + Sca - 1 + population in the bone marrow at week 19. (H) 2, 500 lineage-negative bone marrow cells from LysM-Cre + Flt3 ITD Tet2 +/- mouse were plated in methylcellulose-based media and treated with 10 µM NT ASO or TLK2 ASO, either alone or in combination with 200 nM gilteritinib. Colonies were counted on day 6. Data was presented in duplicates. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001) as determined by one-way ANOVA.
    Figure Legend Snippet: TLK2 ASO in combination with gilteritinib decreases leukemic burden in a murine model of AML. (A) A schematic representation of a murine AML bone marrow transplantation model. 1e6 lineage (Lin - )-depleted CD45.2 + LysM-Cre + Flt3 ITD Tet2 +/- bone marrow cells were injected into lethally irradiated CD45.1 + recipients. Mice were treated with NT ASO, TLK2 ASO, NT ASO + gilteritinib, or TLK2 ASO + gilteritinib. (B) TLK2 expression in peripheral blood at week 17. (C) Spleen size measured by ultrasound at 14 weeks post-transplantation. (D) Endpoint spleen weights at 19 weeks post-transplantation. (E) Spleen images from each treatment group. (F) Leukemic burden in the bone marrow at 19 weeks post-transplantation was measured by flow cytometry using CD45.2 + and myeloid marker Ly6GLy6C. (G) Number of Lin - c-Kit + population and Lin - c - Kit + Sca - 1 + population in the bone marrow at week 19. (H) 2, 500 lineage-negative bone marrow cells from LysM-Cre + Flt3 ITD Tet2 +/- mouse were plated in methylcellulose-based media and treated with 10 µM NT ASO or TLK2 ASO, either alone or in combination with 200 nM gilteritinib. Colonies were counted on day 6. Data was presented in duplicates. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001) as determined by one-way ANOVA.

    Techniques Used: Transplantation Assay, Injection, Irradiation, Expressing, Flow Cytometry, Marker



    Similar Products

    old boyj cd45 1 recipient mice  (Jackson Laboratory)
    86
    Jackson Laboratory old boyj cd45 1 recipient mice
    TLK2 ASO in combination with gilteritinib decreases leukemic burden in a murine model of AML. (A) A schematic representation of a murine AML bone marrow transplantation model. 1e6 lineage (Lin - )-depleted <t>CD45.2</t> + LysM-Cre + Flt3 ITD Tet2 +/- bone marrow cells were injected into lethally <t>irradiated</t> <t>CD45.1</t> + recipients. Mice were treated with NT ASO, TLK2 ASO, NT ASO + gilteritinib, or TLK2 ASO + gilteritinib. (B) TLK2 expression in peripheral blood at week 17. (C) Spleen size measured by ultrasound at 14 weeks post-transplantation. (D) Endpoint spleen weights at 19 weeks post-transplantation. (E) Spleen images from each treatment group. (F) Leukemic burden in the bone marrow at 19 weeks post-transplantation was measured by flow cytometry using CD45.2 + and myeloid marker Ly6GLy6C. (G) Number of Lin - c-Kit + population and Lin - c - Kit + Sca - 1 + population in the bone marrow at week 19. (H) 2, 500 lineage-negative bone marrow cells from LysM-Cre + Flt3 ITD Tet2 +/- mouse were plated in methylcellulose-based media and treated with 10 µM NT ASO or TLK2 ASO, either alone or in combination with 200 nM gilteritinib. Colonies were counted on day 6. Data was presented in duplicates. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001) as determined by one-way ANOVA.
    Old Boyj Cd45 1 Recipient Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/old+boyj+cd45+1+recipient+mice/pmc13006219-73-12-17?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    old boyj cd45 1 recipient mice - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    TLK2 ASO in combination with gilteritinib decreases leukemic burden in a murine model of AML. (A) A schematic representation of a murine AML bone marrow transplantation model. 1e6 lineage (Lin - )-depleted CD45.2 + LysM-Cre + Flt3 ITD Tet2 +/- bone marrow cells were injected into lethally irradiated CD45.1 + recipients. Mice were treated with NT ASO, TLK2 ASO, NT ASO + gilteritinib, or TLK2 ASO + gilteritinib. (B) TLK2 expression in peripheral blood at week 17. (C) Spleen size measured by ultrasound at 14 weeks post-transplantation. (D) Endpoint spleen weights at 19 weeks post-transplantation. (E) Spleen images from each treatment group. (F) Leukemic burden in the bone marrow at 19 weeks post-transplantation was measured by flow cytometry using CD45.2 + and myeloid marker Ly6GLy6C. (G) Number of Lin - c-Kit + population and Lin - c - Kit + Sca - 1 + population in the bone marrow at week 19. (H) 2, 500 lineage-negative bone marrow cells from LysM-Cre + Flt3 ITD Tet2 +/- mouse were plated in methylcellulose-based media and treated with 10 µM NT ASO or TLK2 ASO, either alone or in combination with 200 nM gilteritinib. Colonies were counted on day 6. Data was presented in duplicates. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001) as determined by one-way ANOVA.

    Journal: Frontiers in Oncology

    Article Title: Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia

    doi: 10.3389/fonc.2026.1659341

    Figure Lengend Snippet: TLK2 ASO in combination with gilteritinib decreases leukemic burden in a murine model of AML. (A) A schematic representation of a murine AML bone marrow transplantation model. 1e6 lineage (Lin - )-depleted CD45.2 + LysM-Cre + Flt3 ITD Tet2 +/- bone marrow cells were injected into lethally irradiated CD45.1 + recipients. Mice were treated with NT ASO, TLK2 ASO, NT ASO + gilteritinib, or TLK2 ASO + gilteritinib. (B) TLK2 expression in peripheral blood at week 17. (C) Spleen size measured by ultrasound at 14 weeks post-transplantation. (D) Endpoint spleen weights at 19 weeks post-transplantation. (E) Spleen images from each treatment group. (F) Leukemic burden in the bone marrow at 19 weeks post-transplantation was measured by flow cytometry using CD45.2 + and myeloid marker Ly6GLy6C. (G) Number of Lin - c-Kit + population and Lin - c - Kit + Sca - 1 + population in the bone marrow at week 19. (H) 2, 500 lineage-negative bone marrow cells from LysM-Cre + Flt3 ITD Tet2 +/- mouse were plated in methylcellulose-based media and treated with 10 µM NT ASO or TLK2 ASO, either alone or in combination with 200 nM gilteritinib. Colonies were counted on day 6. Data was presented in duplicates. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001) as determined by one-way ANOVA.

    Article Snippet: 1e6 lineage negative cells and supporting cells were retro-orbitally injected into 6-weeks old BoyJ CD45.1 recipient mice (Jackson Lab #002014) which were lethally irradiated with two doses of 500 and 450 cGy 4 hours apart.

    Techniques: Transplantation Assay, Injection, Irradiation, Expressing, Flow Cytometry, Marker